INTRODUCTION {#s1}
============

Most cases of thyroid cancer, the most common endocrine malignancy, have a generally favorable prognosis \[[@R1]\]. However, 10--15% of thyroid cancers present as persistent or recurrent disease, sometimes resulting in terminal disease \[[@R2], [@R3]\]. To develop molecular markers able to predict these persistent or recurrent cases, research over the last decade based on molecular and systems biology has remarkably improved the mechanistic understanding of thyroid carcinogenesis \[[@R4], [@R5]\]. As a result of our increased understanding of the pathogenesis of thyroid cancer, aberrant activation of MEK/ERK and/or phosphatidylinositol-3 kinase (PI3K)/AKT pathways are known to play fundamental roles in thyroid cancer progression \[[@R6], [@R7]\].

In addition to sustaining proliferative signaling, metabolic alterations driven by oncogenic signaling pathways are now understood to contribute to the development of thyroid carcinogenesis \[[@R8]\]. Aerobic glycolysis, also called the "Warburg effect", drives metabolic remodeling in PTEN-deficient thyroid cells \[[@R9]\]. Crosstalk between oncogenic BRAFV600E kinase and the mitochondria also increases glycolytic activity in thyroid cancer cells \[[@R10]\]. However, our recent observation indicated that a subset of papillary thyroid cancer (PTC) is able to sustain mitochondrial capacity \[[@R11]\]. In agreement with this finding, human melanomas exhibit increased mitochondrial capacity and resistance to oxidative stress through the activation of melanocyte lineage-specification transcription factor (MITF) and PGC1α (PPARGC1A) \[[@R12], [@R13]\]. Furthermore, addiction to oxidative phosphorylation (OxPhos) generates drug resistance against PLX4720, a BRAF inhibitor, in BRAF-mutated melanomas \[[@R14]\].

Leucine zipper EF-hand containing transmembrane protein 1 (LETM1), which was first discovered in patients with Wolf-Hirschhorn syndrome (WHS), has been reported to enhance mitochondrial Ca^2+^ transport and cell proliferation \[[@R15]--[@R17]\]. Silencing of LETM1 expression influenced autophagy activity and provoked AMPK activation and cell cycle arrest \[[@R17]\]. Furthermore, LETM1 promotes AKT/PKB activation by inhibition of C-terminal modulator protein (CTMP) \[[@R18]\]. Supporting the proto-oncogenic properties of LETM1, human multiple tissues arrays have also demonstrated increased expression of LETM1 in various cancers, including breast, head and neck cancers \[[@R19], [@R20]\].

In this study, we found that up-regulation of LETM1 expression is related to platelet-derived growth factor (PDGF) signaling, supporting the role of LETM1 in cell proliferation and energy metabolism in PTC. Remarkably, LETM1 over-expression is also linked to nuclear retention of Yes-associated protein 1 (YAP1), which upregulates PDGFB at the transcriptional level, while LETM1 silencing has the opposite effect. Based on these findings, up-regulation of LETM1 appears to play a critical role in altering mitochondrial metabolism and tumor behavior in PTC carcinogenesis through YAP1 transactivation.

RESULTS {#s2}
=======

Up-regulation of LETM1 linked to PDGF signal pathway {#s2_1}
----------------------------------------------------

First, to verify our hypothesis that LETM1 expression might be linked to the cell growth signaling pathway, we performed correlation analysis using public data (EPFL/LISP BXD CD Muscle Affy Mouse Gene 1.0 ST (Nov12) RMA Exon Level, muscle mRNA; number of samples = 42) deposited at GeneNetwork. Compatible with previous reports, *Letm1* showed positive correlations with *Ndufv1* (encoding NADH:Ubiquinone Oxidoreductase Core Subunit V1), *Sdhb* (Succinate Dehydrogenase Complex Iron Sulfur Subunit B) (Figure [1A](#F1){ref-type="fig"}), *Cyc1* (Cytochrome C1), *Atp5b* (ATP Synthase, H^+^ Transporting, Mitochondrial F1 Complex, Beta Polypeptide) (Figure [1B](#F1){ref-type="fig"}), *Mrpl12* (Mitochondrial Ribosomal Protein L12) (INIA Adrenal Affy MoGene 1.0ST (Jun12) RMA Males, adrenal mRNA; number of samples = 46, [Supplementary Figure S1A](#SD1){ref-type="supplementary-material"}), *Ndufb7* (NADH:Ubiquinone Oxidoreductase Subunit B7), *Cox5b* (Cytochrome C Oxidase Subunit 5B), *Uqcrc1* (Ubiquinol-Cytochrome C Reductase Core Protein I), *Mrpl39* (Mitochondrial Ribosomal Protein L39) and *Tomm40* (Translocase Of Outer Mitochondrial Membrane 40) (EPFL/LISP BXD CD Muscle Affy Mouse Gene 1.0 ST (Nov12) RMA Exon Level) (Figure [1C](#F1){ref-type="fig"}, [Supplementary Figure S1B--S1D](#SD1){ref-type="supplementary-material"}). Interestingly, *Letm1* expression positively correlated with mechanistic target of rapamycin (*Mtor*) and phosphoinositide-3-kinase, regulatory subunit 4 (*Pik3r4*) (Figure [1D](#F1){ref-type="fig"}). In addition, Gene Set Enrichment Analysis (GSEA) using public repository data (GSE33630, expression profiling by array of 11 anaplastic thyroid carcinomas (ATC), 49 PTC and 45 normal thyroids (N)) showed that platelet-derived growth factor (PDGF) signaling pathway was coordinately enriched in PTC with high LETM1 expression (*P* = 0.022, FDR q-value \< 0.05, Figure [1E](#F1){ref-type="fig"}). To support our findings from GeneNetwork and GSE33630, we performed GSEA using public repository data from "The Cancer Genome Atlas". The comparison of mean RPKM (Reads Per Kilobase per Million mapped reads) between normal and tumor mRNAs indicated statistically significant increase of LETM1 expression in PTC (Figure [2A](#F2){ref-type="fig"}). In the TCGA analysis, 15 cases out of 505 PTC (total THCA) showed high expression of LETM1. Although 15 was a small proportion of the total PTCs in THCA, only a small subset of PTCs had demonstrated aggressive behavior in the clinical setting, therefore we decided to select 30 cases; 15 cases with the highest expression (Highest LETM1 PTC) and 15 cases with the lowest expression (Lowest LETM1 PTC) of LETM1. Performing GSEA based on TPM (Transcripts per Million), gene sets related to oxidative phosphorylation, glycolysis and gluconeogenesis and insulin signaling pathway were coordinately enriched in high LETM1 group ([Supplementary Table S1](#SD1){ref-type="supplementary-material"}, Figure [2B](#F2){ref-type="fig"}). Remarkably, volcano plot generated from selected 30 TCGA cases used in our GSEA indicated significantly increased fold changes of representative genes of PDGF signaling pathway such as PDGFB, platelet-derived growth factor receptor, beta polypeptide (PDGFRB), Thrombospondin-4 (THBS4), collagen, type IV, alpha 1 (COL4A1), platelet derived growth factor D (PDGFD) and collagen, type IV, alpha 5 (COL4A5) (Figure [2C](#F2){ref-type="fig"}). qRT-PCR experiments using our own cDNA samples from patients with PTC supported our GSEA analysis. PDGFB, PDGFRB and THBS4 were increased in PTC with high LETM1 expression (high LETM1 PTC, Figure [2D](#F2){ref-type="fig"}, [Supplementary Table S2](#SD1){ref-type="supplementary-material"}). Many hormones or hormone-binding proteins such as PDGFB are enhanced by YAP1 overexpression in MCF10A cells. Although mRNA of YAP1 was not increased, the mRNA expression of coronin 2B (CORO2B), a representative YAP1 target gene, was significantly increased in high LETM1 PTC (Figure [2C and 2D](#F2){ref-type="fig"}) \[[@R21]\].

![Correlation of LETM1 expression with genes related to OxPhos and cellular proliferation signaling\
(**A**--**D**) Correlation of *Letm1* mRNA expression with genes related to OxPhos and mTOR/PI3K signaling from public repository data in GeneNetwork (a free scientific web resource, <http://www.genenetwork.org/>; INIA Adrenal Affy MoGene 1.0ST (Jun12) RMA Males, EPFL/LISP BXD CD Muscle Affy Mouse Gene 1.0 ST (Nov12) RMA Exon Level). (**E**) Correlation of *LETM1* mRNA expression with genes related to the PDGF signaling pathway from the Gene Expression Omnibus (GEO) of NCBI (Gene expression data available at [www.ncbi.nlm.nih.gov/projects/geo](http://www.ncbi.nlm.nih.gov/projects/geo); accession no. GSE33630).](oncotarget-07-66728-g001){#F1}

![Correlation of LETM1 expression with genes related to OxPhos and cellular proliferation signaling\
(**A**) Comparison of *LETM1* RPKM values between normal thyroid tissues (NL) and papillary thyroid cancer (CA) using public data from The Cancer Genome Atlas Research Network (TCGA, <http://cancergenome.nih.gov/>). (**B**) GSEA using PTCs with the highest and lowest *LETM1* expression levels (each group *n* = 15). (**C**) Volcano plot analysis indicating increased RPKM values (log2 fold change) of central components of the PDGF signaling pathway. (**D**) qRT-PCR using validation cDNA sets from the study subjects. White and blue bars indicate matched normal thyroid tissues and PTC, respectively (each group *n* = 7). Comparisons of the average means were performed with the Mann-Whitney *U-test*. Data are presented as the means ± SD. ^\*\*^ *P* \< 0.01, ^\*\*\*^ *P* \< 0.001. All *P*-values are two-sided.](oncotarget-07-66728-g002){#F2}

Effects of LETM1 on growth factor signaling and OxPhos {#s2_2}
------------------------------------------------------

To confirm the changes in expression of mRNAs encoding for regulators of growth factor signaling and OxPhos, we performed western blot analysis using samples derived from human thyroid cancer tissues. As shown in Figure [3A](#F3){ref-type="fig"}, we observed that PTC showing high LETM1 expression (high LETM1 PTC) also had high expression of components of OxPhos, such as SDHB, UQCRC2, ATP5A and HSP60, a mitochondrial heat shock protein. With regard to growth factor signaling intermediates, AKT phosphorylation (pAKT) and PDGFB were markedly increased in high LETM1 PTC, whereas pAKT and PDGFB were decreased in PTC with low LETM1 expression (low LETM1 PTC), compared to paired normal thyroid tissue (Figure [3A and 3B](#F3){ref-type="fig"}). When we overexpressed LETM1 in a human PTC cell line (BCPAP), we observed a coordinate increase in protein levels of OxPhos components (SDHB, UQCRC2 and MTCO1; Figure [3C](#F3){ref-type="fig"}). Interestingly, LETM1 overexpressing BCPAP cells showed increased glycolysis and oxygen consumption, implying that these cells uptake glucose rapidly and generate large amounts of ATP by OxPhos ([Supplementary Figure S2](#SD1){ref-type="supplementary-material"}). Furthermore, supporting the relationship between LETM1 with growth factor signaling, LETM1 overexpression increased AKT and pAKT in BCPAP (Figure [3C and 3D](#F3){ref-type="fig"}), associated with elevated protein levels of PDGFB and mRNA expression of PDGFB, PDGFBR and THBS4 (Figure [3C and 3E](#F3){ref-type="fig"}).

![Correlation of LETM1 expression with oxidative phosphorylation (OxPhos) and cellular proliferation signaling\
(**A** and **B**) Representative western blot analyses indicating the association between LETM1 and OxPhos/PDGFB in tissue samples from human papillary thyroid cancers and paired normal thyroid (A), and quantification of total and phospho-AKT band intensities. White and green bars indicate matched normal thyroid tissues and PTC, respectively (B). (**C** to **E**) Representative western blot analyses indicating the effect of LETM1 overexpression on OxPhos/PDGFB in BCPAP cells (C) and quantification of total and phospho-AKT band intensities (D). qPCR analyses showing the effect of transient overexpression of LETM1 on mRNA expression of PDGFB, PDGFRB and THBS4 in BCPAP cells (E). White and green bars indicate BCPAP transfected with pcDNA3.1 and pcDNA3.1/LETM1-Myc plasmids, respectively. Comparisons of the average means were performed with the Mann-Whitney *U-test*. Data are presented as the means ± SD. ^\*\*^*P* \< 0.01, ^\*\*\*^ *P* \< 0.001. All *P*-values are two-sided.](oncotarget-07-66728-g003){#F3}

Up-regulation or silencing of LETM1 is linked to YAP1 localization {#s2_3}
------------------------------------------------------------------

YAP1 transactivation is regulated by subcellular localization of YAP1 \[[@R22]\]. When LATS phosphorylates YAP1 at serine 127 residue, YAP1 is exported from nucleus and transactivation is turned off \[[@R21]\]. In contrast, activation of G-protein coupled receptors or receptor tyrosine kinase signaling promotes YAP1 nuclear translocation and YAP1-dependent transcription via PI3K-AKT/PKB signaling activation \[[@R23], [@R24]\]. Consistent with this regulatory mechanism of YAP1 subcellular localization, when we performed double immunofluorescence (IF) staining for YAP1 and LETM1, we consistently observed that LETM1 overexpression increased the nuclear accumulation of YAP1 in BCPAP cells (Figure [4A](#F4){ref-type="fig"}). Next, to investigate the involvement of the PI3K-PKB/AKT signaling pathway in YAP1 regulation by LETM1, we treated BCPAP cells with LY294002, a PI3K inhibitor, and performed IF staining. Remarkably, LY294002 was able to abolish the nuclear signal of YAP1 (Figure [4A](#F4){ref-type="fig"}), which was associated with the disappearance of AKT phosphorylation (Figure [4B](#F4){ref-type="fig"}). To verify YAP1 regulation by LETM1, we also treated BCPAP cells with siLETM1 and observed a markedly decreased YAP1 nuclear signal (Figure [4C](#F4){ref-type="fig"}), accompanied by disappearance of AKT phosphorylation (Figure [4D](#F4){ref-type="fig"}). Taken together, nuclear accumulation of YAP1 could be prevented by the inactivation of PI3K-AKT signaling or down-regulation of LETM1.

![Subcellular localization of YAP1 is modified by LETM1 over-expression or silencing\
(**A**) Representative immunofluorescence staining indicating increased nuclear YAP1 translocation as a result of LETM1 overexpression, mediated via the PI3K-PKB/AKT signaling pathway in BCPAP cells. White arrow indicates nucleus. (**B**) Representative western blot analyses indicating the effect of LY294002 on AKT phosphorylation. (**C**) Immunofluorescence staining demonstrating the effect of siLETM1 on YAP1 nuclear signal. White arrows indicate nuclei. SC: scramble SiRNA. (**D**) Western blot analyses showing the effect of siLETM1 on total/phospho-PKB/AKT and PDGFB in BCPAP cells. (**E**) qPCR analyses showing the effect of LETM1 silencing on mRNA expression of PDGFB, PDGFRB and THBS4 in BCPAP cells. (**F**) Western blot analyses showing the effect of siLETM1 on total/phospho-PKB/AKT and OxPhos/PDGFB in 8505C cells. (**G**) qPCR analyses showing the effect of LETM1 silencing on mRNA expression of PDGFB, PDGFRB and THBS4 in 8505C cells. Comparisons of the mean values were performed with the Mann-Whitney *U-test*. Data are presented as the means ± SD. ^\*\*^ *P* \< 0.01, ^\*\*\*^ *P* \< 0.001. All *P*-values are two-sided. (**H**) Representative results of immunohistochemical staining using anti-LETM1 and YAP1 antibodies (200 x). Case \#1, cytosolic localization of YAP1 in PTCs showing no LETM1 staining. Cases \#2--4, nuclear accumulation of YAP1 in PTCs showing strong LETM1 staining. Red boxes indicate the areas magnified at the next high power field (far right panel).](oncotarget-07-66728-g004){#F4}

Clinical impact of LETM1 up-regulation in thyroid cancer {#s2_4}
--------------------------------------------------------

Reinforcing our observations regarding the relationship of LETM1 with cellular growth signaling, LETM1 silencing resulted in decreased protein levels of PDGFB and mRNA expression of PDGFB, PDGFBR and THBS4 in BCPAP cells (Figure [4D and 4E](#F4){ref-type="fig"}) and 8505C cells (human anaplastic thyroid cancer cell line, Figure [4F and 4G](#F4){ref-type="fig"}). Furthermore, consistent with the IF data, PTC with high immunohistochemical staining (IHC-P) scores of LETM1 showed moderate to strong signals for nuclear YAP1 and PDGFB (Figure [4H](#F4){ref-type="fig"}, Table [1](#T1){ref-type="table"}). To investigate the impact of LETM1 over-expression on clinical outcome, we performed statistical analyses of the relationship between LETM1 IHC staining intensities and clinico-pathological parameters. Remarkably, the lymphovascular invasion (LVI) and lymph node metastasis (LNM) were more frequently observed in patients with PTC showing moderate to strong LETM1 staining intensities (Table [2](#T2){ref-type="table"}). In addition, multivariate analysis clearly indicated that moderate to strong LETM1 staining intensities increased risks of LVI and LNM even after adjusting the clinico-pathological parameters (OR = 4.724, CI = 1.423--15.688, Table [3](#T3){ref-type="table"}; OR = 2.333, CI = 1.059--5.141, Table [4](#T4){ref-type="table"}).

###### Protein expression levels of YAP1 and PDGFB according to LETM1 expression status

                      Patients with no/focal staining   Patients with moderate strong staining   *P*-value
  ------------------- --------------------------------- ---------------------------------------- -----------
  YAP1 staining                                                                                  
   Focal              19 (20.2)                         9 (10.8)                                 
   Moderate           58 (61.7)                         55 (66.3)                                0.213
   Strong             17 (18.1)                         19 (22.9)                                
  YAP1 localization                                                                              
  Cytosol             17 (18.1)                         1 (1.2)                                  
  Nucleus             51 (54.3)                         60 (72.3)                                0.001
  Cytosol+ Nucleus    26 (27.6)                         22 (26.5)                                
  PDGFB staining                                                                                 
  Negative            17 (18.1)                         3 (3.6)                                  
   Focal              26 (27.6)                         16 (19.3)                                0.007
   Moderate           22 (23.4)                         24 (28.9)                                
   Strong             29 (30.9)                         40 (48.2)                                

All *P*-values were calculated from comparisons between three or four groups in linear by linear association.

###### Clinicopathologic characteristics according to LETM1 expression status

                             Patients with no/focal staining   Patients with moderate to strong staining   *P*-value
  -------------------------- --------------------------------- ------------------------------------------- ----------------------------------------------
  Age (years)                42.4 ± 14.8                       46.5 ± 14.2                                 0.111[^a^](#tfn_001){ref-type="table-fn"}
  Gender (Male:Female)       18 (19.1) : 76 (80.9)             13 (15.7) : 70 (84.3)                       0.543[^b^](#tfn_002){ref-type="table-fn"}
  Tumor Size (cm)            2.30 ± 1.20                       2.23 ± 0.93                                 0.661[^a^](#tfn_001){ref-type="table-fn"}
  Extrathyroidal Extension                                                                                 
  Negative                   31 (33.0)                         24 (28.9)                                   0.560[^b^](#tfn_002){ref-type="table-fn"}
   Positive                  63 (67.0)                         59 (71.1)                                   
  Multifocality                                                                                            
   Negative                  68 (72.3)                         64 (77.1)                                   
   Positive                  26 (27.7)                         19 (22.9)                                   0.467[^b^](#tfn_002){ref-type="table-fn"}
  Bilaterality                                                                                             
   Negative                  77 (81.9)                         70 (84.3)                                   0.668[^b^](#tfn_002){ref-type="table-fn"}
   Positive                  17 (18.1)                         13 (15.7)                                   
  Lymphovascular invasion                                                                                  
   Negative                  72 (76.6)                         39 (47.0)                                   \< 0.001[^b^](#tfn_002){ref-type="table-fn"}
   Positive                  22 (23.4)                         44 (53.0)                                   
  Lymph node metastasis                                                                                    
   Negative                  53 (56.4)                         31 (37.3)                                   0.011[^b^](#tfn_002){ref-type="table-fn"}
   Positive                  41 (43.6)                         52 (62.7)                                   
  Tumor Stage                                                                                              
   T1                        17 (18.1)                         18 (21.7)                                   
   T2                        14 (14.9)                         6 (7.2)                                     0.312[^b^](#tfn_002){ref-type="table-fn"}
   T3                        57 (60.6)                         56 (67.5)                                   
   T4a/b                     6 (6.4)                           3 (3.6)                                     
  Lymph Node Stage                                                                                         
   N0                        53 (56.4)                         31 (37.3)                                   
   N1a                       31 (33.0)                         39 (47.0)                                   0.041[^b^](#tfn_002){ref-type="table-fn"}
   N1b                       10 (10.6)                         13 (15.7)                                   
  Distant Metastasis                                                                                       
   Negative                  93 (98.9)                         80 (96.4)                                   0.255[^b^](#tfn_002){ref-type="table-fn"}
   Positive                  1 (1.1)                           3 (3.6)                                     
  TNM Stage                                                                                                
   I                         46 (48.9)                         32 (38.6)                                   
   II                        2 (2.1)                           4 (4.8)                                     0.658[^c^](#tfn_003){ref-type="table-fn"}
   III                       21 (22.3)                         19 (22.9)                                   
   IVA                       22 (23.4)                         26 (31.3)                                   
   IVB                       2 (2.1)                           1 (1.2)                                     
   IVC                       1 (1.2)                           1 (1.2)                                     

Data are presented as means ± SD and *P*-values were calculated by an independent samples *t*-test.

*P*-values were calculated by pair-wise comparison using Pearson\'s χ^2^ test or Fisher\'s exact test.

*P*-values were calculated by comparison between three or four groups in linear by linear association.

###### Multivariate analysis of the association of lymphovascular invasion (LVI) with LETM1 expression levels

                                                                     LVI                    
  ------------------------------------------------------------------ ------- -------------- ----------
  Moderate to strong staining [^a^](#tfn_004){ref-type="table-fn"}   3.690   1.934--7.042   \< 0.001
  Moderate to strong staining [^b^](#tfn_005){ref-type="table-fn"}   3.900   1.886--8.066   \< 0.001
  Moderate to strong staining [^c^](#tfn_006){ref-type="table-fn"}   3.455   1.537--7.766   0.003

Adjusted for age and sex.

In addition to adjustment^a^, adjusted for tumor size, multifocality, bilaterality, ETE, LNM, T staging, and M staging.

In addition to adjustment^b^, adjusted for YAP1 staining, YAP1 localization and PDGFB staining.

Abbreviations: ETE, extrathyroidal extension; LNM, lymph node metastasis; LVI, lymphovascular invasion; CI, confidence interval.

###### Multivariate analysis of the association of lymph node metastases (LNM) with LETM1 expression levels

                                                                     LNM                    
  ------------------------------------------------------------------ ------- -------------- -------
  Moderate to strong staining [^a^](#tfn_007){ref-type="table-fn"}   2.177   1.189--3.986   0.012
  Moderate to strong staining [^b^](#tfn_008){ref-type="table-fn"}   2.388   1.115--5.114   0.025
  Moderate to strong staining [^c^](#tfn_009){ref-type="table-fn"}   3.043   1.282--7.225   0.012

Adjusted for age and sex.

In addition to adjustment^a^, adjusted for tumor size, multifocality, bilaterality, ETE, LVI, T staging, and M staging.

In addition to adjustment^b^, adjusted for YAP1 staining, YAP1 localization and PDGFB staining.

Abbreviations: ETE, extrathyroidal extension; LNM, lymph node metastasis; LVI, lymphovascular invasion; CI, confidence interval.

DISCUSSION {#s3}
==========

LETM1, localized in the inner membrane of mitochondria, is an element of Ca^2+^/H^+^ antiporter and functions in mitochondrial ATP production and biogenesis \[[@R15]\]. Recently, some authors have claimed that high expression levels of LETM1 have correlation with poor prognostic factors in human malignancies \[[@R19], [@R20]\]. In our study, compatible to previous knowledge, the correlation analysis using GeneNetwork indicated that Letm1 mRNA expression levels had strong positive correlation with mRNA expressions of genes related to OxPhos such as Ndufv1, Sdhb, Cyc1, Atp5b and so forth. Interestingly, our GSEA using repository data by the International Pathology Panel of the Chernobyl Tissue Bank (GSE33630) indicated that PDGF signaling was coordinately enriched in high LETM1 expression PTC. Furthermore, our analyses using TCGA database consistently indicated that PTCs have high expression levels of LETM1 compared to normal thyroid tissue and that high LETM1 expression was significantly associated with expression of genes related to OxPhos. Remarkably, high LETM1 expression was also positively related to glycolysis/gluconeogenesis and cellular growth signaling pathway gene sets. Otto Warburg hypothesized that cancer cell proliferation is facilitated by anaerobic glycolysis known as fermentation. As a result, cancer cell should have dysfunctional mitochondria \[[@R25], [@R26]\]. However, metabolic heterogeneity may have an impact on tumor behavior and drug responsiveness \[[@R11], [@R13]\]. Our study implied that the mitochondrial protein LETM1 may enhance ATP generation in cancer cells. Based on the resulting increase in energy supply, cancer cells might be able to generate their own proliferation signal.

The binding of insulin with its ligand specific receptor increases glucose metabolism, lipid synthesis and cellular proliferation via PKB/AKT signaling \[[@R27], [@R28]\]. In fact, dysregulation of PKB/AKT signaling provokes a broad range of diseases such as cancer, diabetes and heart disease \[[@R29], [@R30]\]. CTMP was first identified as a PKB/AKT binding partner with tumor-suppressor function. PKB/AKT is negatively regulated by the binding of CTMP with the C-terminal regulatory domain of pPKB/AKT \[[@R31], [@R32]\]. Together with CTMP, LETM1 is associated with mitochondrial morphology via optic atrophy 1 (OPA1) regulation \[[@R33]\]. And, a recent report demonstrated that LETM1 and CTMP participate in insulin signaling via regulation of PKB/AKT activity \[[@R18]\]. Our GSEA and qRT-PCR results also supported that these LETM1-CTMP-PKB/AKT signaling network might be operational. Taken together, these data suggest that LETM1 might enhance AKT activation. However, this hypothesis must be tested in future studies.

A new finding in this study was the relation of LETM1 with PDGF signaling via YAP1 transactivation. Mammalian Hippo signaling induces inactive YAP1 phosphorylation through MST1/2-LATS1/2 signal propagation \[[@R22], [@R34]\]. Whereas, activation of receptor tyrosine kinase (RTK) or G-protein coupled receptor (GPCR) turns off Hippo signaling via PI3K activation \[[@R23], [@R24], [@R35]\]. Finally, YAP1 moves into nucleus and induces the transcriptions of YAP1 target genes with cell-type specific manner \[[@R36]\]. Based on our volcano plot presenting increased mRNA expressions of PDGFB and CORO2B, representative YAP1 target genes \[[@R21]\], we hypothesized that YAP1 transactivation by PI3K/AKT might be linked to PDGFB up-regulation in high LETM1 PTC, supported by the data from our IF and IHC-P. PDGF is a growth factor promoting cell growth and division especially in blood vessel formation \[[@R37]\]. Up-regulation of PDGF signal in cancer cells results in increased proliferation and cell migration by MEK/ERK activation and lamellipodia/filopodia formation \[[@R38], [@R39]\]. Compatibly, LETM1 over-expression increased risks of LVI and LNM in our clinical data analyses.

In summary, our bioinformatics and clinical analyses consistently indicated that LETM1 is associated with mitochondrial function and PKB/AKT signaling. Moreover, YAP1 transactivation might have a pivotal role in LETM1-induced PDGF signaling activation. Future study will be focusing on further mechanistic explanations of LETM1-PKB/AKT-YAP1-PDGF signal pathway to develop new druggable targets for invasive or metastatic thyroid cancers.

MATERIALS AND METHODS {#s4}
=====================

Subjects and clinical data {#s4_1}
--------------------------

A total of 177 patients (31 male and 146 female) who underwent thyroidectomy with central neck node dissection for the management of conventional PTC between March 2014 and December 2014 at Severance Hospital, Yonsei Cancer Center, Seoul, South Korea were enrolled in the study. Samples were taken from the center of the cancer and validated by hematoxylin-eosin staining. On histological examination, \> 90% of the cells were confirmed to be thyroid cancer cells. All protocols were approved by the institutional review board of Severance Hospital.

RNA isolation and real-time PCR {#s4_2}
-------------------------------

Total RNA was extracted from fresh frozen tissues by Trizol reagent (Invitrogen, Carlsbad, CA, USA), and the RNA quality was verified using a 2100 Bioanalyzer System (Agilent Technologies, Santa Clara, CA, USA). Complementary DNA (cDNA) was prepared from total RNA using M-MLV Reverse Transcriptase (Invitrogen) and oligo-dT primers (Promega, Madison, WI, USA). Quantative RT-PCR (qRT-PCR) was performed using a QuantiTect SYBR^®^ Green RT-PCR Kit (Qiagen, Valencia, CA, USA). Relative expression was calculated using the StepOne™ Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). Primers used in qRT-PCR are listed in [Supplementary Table S2](#SD1){ref-type="supplementary-material"}. qRT-PCR experiments were repeated three times, and each experiment was performed in triplicate.

Cell culture and transfection {#s4_3}
-----------------------------

The human thyroid cancer cell lines BCPAP and 8505C were cultured in RPMI-1640 medium (Hyclone, UT, USA) containing 10% fetal bovine serum (Life Technologies, Carlsbad, CA) and 1% penicillin/streptomycin (Life Technologies). The cells were transfected transiently with pcDNA3.1/LETM1-Myc using jetPEI (Polyplus transfection, Illkirch, France).

Small interfering RNA (siRNA) transfection and reagents {#s4_4}
-------------------------------------------------------

To knock down endogenous LETM1, cells were transiently transfected with 10 μM chemically synthesized siRNAs (sc-89079, Santa Cruz Biotechnology) targeting LETM1 or with non-silencing control siRNA using Transfection Reagent, according to the manufacturer\'s recommendations. LY294002 was purchased from Cayman (Ann Arbor, MI, USA). All experiments were performed in duplicate and were repeated at least three times.

Immunoblot analysis {#s4_5}
-------------------

Immunoblot analysis was performed using standard methods with commercially available antibodies: anti-LETM1 (HPA 011029, Sigma-Aldrich, St. Louis, Missouri, USA), anti- Phospho-AKT (Ser473) (\#9271, Cell Signaling, Danvers, MA, USA), anti-AKT (\#9272, Cell Signaling), anti-YAP1 (\#14074, Cell Signaling), anti-PDGFB (HPA-011972, Sigma), Mitoprofile Total OxPhos Rodent WB Antibody Cocktail (Mitosciences/Abcam, Cambridge, MA, ab110413), anti-HSP60 (\#12165, Cell Signaling) and anti-Actin (sc-1616, Santa Cruz Biotechnology, Dallas, TX, USA). The signal intensities on western blots were quantified using ImageJ software.

Immunofluorescence staining {#s4_6}
---------------------------

The cells were plated on coverslips in six-well plates. At 2 days after transient transfection with pcDNA3.1/Myc-LETM1 using jetPEI transfection reagent (Polyplus Transfection, Illkirch, France) (or At 2 days after transfection with siRNA-LETM1 using RNAiMAX transfection reagent (Invitrogen, CA, USA)), the cells were subjected to immunofluorescence staining as described previously \[[@R40]\]. The cells were fixed and permeabilized using conventional methods, and then blocked in 1% bovine serum albumin (BSA). Thereafter, the cells were incubated with anti-YAP1 (\#14074, Cell Signaling) and anti-LETM1 (sc-271234, Santa Cruz Biotechnology, Dallas) antibodies for double immunostaining at a 1:100 dilution in 1% BSA for 24 h at 4°C. After washing, cells were incubated with FITC (Fluorescein isothiocyanate)-conjugated pure donkey anti-rabbit and Cy3 (Cyanine)-conjugated pure donkey anti-mouse antibodies (Jackson ImmunoResearch Laboratories Inc., West Grove, PA, USA) at a 1:100 dilution in 1% BSA for 1 h at room temperature in dark. After washing the cells, cells on the coverslips were mounted on glass slides using mounting medium with 4, 6-diamidino-2-phenylindole (DAPI) (Vector Laboratories, Inc., Burlingame, CA, USA) and visualized with a Zeiss LSM710 confocal microscope (Carl Zeiss AG, Jena, Germany). All experiments were performed in duplicate and were repeated at least five times.

Measurement of oxygen consumption rate and glycolysis {#s4_7}
-----------------------------------------------------

Cells overexpressing or silenced with respect to LETM1 were subjected to mitochondrial oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) measurements using an XF-24 analyzer (Seahorse Bioscience Inc, North Billerica, MA). Three baseline measurements of the OCR and ECAR were made.

Immunohistochemical analysis {#s4_8}
----------------------------

Formalin fixed paraffin-embedded (FFPE) tissue sections (4 μm thick) were deparaffinized and re-hydrated in xylene and a graded series of ethanol, respectively. Antigens were retrieved in 0.01 M citrate buffer (pH 6.0) by microwaving for 10 min. To inactivate endogenous peroxidases, the tissue sections were placed in 3% hydrogen peroxide for 5 min and then blocked for 10 min with normal goat serum. The primary antibodies used for this study were anti-LETM1, anti-PDGFB, and anti-YAP1. Staining scores were assigned as follows: 1, no staining; 2, weak or focal staining; 3, moderate staining in most cells; and 4, strong staining in most cells.

Public data and statistical analysis {#s4_9}
------------------------------------

Public repository microarray data from The Cancer Genome Atlas (TCGA, <https://tcga-data.nci.nih.gov/tcga/>) and the Gene Expression Omnibus (GEO) of NCBI (Gene expression data available at [www.ncbi.nlm.nih.gov/projects/geo](https://www.ncbi.nlm.nih.gov/projects/geo); accession no. GSE33630) were subjected to GSEA. Data from the GeneNetwork (a free scientific web resource, <http://www.genenetwork.org/>) were also subjected to analysis. Statistical analysis was carried out using SPSS version 20.0 for Windows (IBM Corporation, Armonk, New York, USA) or GraphPad Prism (GraphPad Software, Inc., San Diego, CA, USA). Data are presented as the means ± SD. All *P*-values are two sided.

SUPPLEMENTARY MATERIAL TABLES AND FIGURES {#s5}
=========================================
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